Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive

被引：231
作者：
van den Heuvel, MW
van Bragt, AJM
Alnabawy, AKM
Kaptein, MCJ
机构：
[1] Organon Int BV, Roseland, NJ 07068 USA
[2] Farma Res BV, Dept Human Drug Res, NL-6531 LB Nijmegen, Netherlands
[3] NV Organon, Dept Clin Pharmacol & Kinet, NL-5340 BH Oss, Netherlands
来源：
CONTRACEPTION | 2005年 / 72卷 / 03期
关键词：
NuvaRing; oral contraceptive; transdermal contraceptive patch; ethinylestradiol; pharmacokinetics;
D O I：
10.1016/j.contraception.2005.03.005
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
This open-label, randomized study compared the pharmacokinetics of ethinylestradiol (EE) from the contraceptive vaginal ring NuvaRing (15 mu g EE/day), the transdermal patch (20 mu g EE/day) and a combined oral contraceptive (COC) containing 30 mu g EE. After 2-8 weeks of synchronization by COC treatment, subjects were randomized to 21 days of treatment with NuvaRing, patch or COC. Analysis of area under the EE concentration-versus-time curve (AUQ during 21 days of treatment showed that exposure to EE in the NuvaRing group was 3.4 times lower than in the patch group (p < .05) and 2.1 times lower than in the pill group (p < .05). Serum EE levels of subjects showed much lower variation with NuvaRing than with the patch or the COC. Thus, exposure to EE was significantly lower with NuvaRing than with the patch and pill methods, demonstrating that NuvaRing is a low-estrogen-dose contraceptive method that also results in low estrogen exposure. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码：168 / 174
页数：7
相关论文
共 11 条
[1]   Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyloestradiol at four application sites [J].
Abrams, LS ;
Skee, DM ;
Natarajan, J ;
Wong, FA ;
Anderson, GD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :141-146
[2]   Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants [J].
Abrams, LS ;
Skee, DA ;
Natarajan, J ;
Wong, FA ;
Lasseter, KC .
CONTRACEPTION, 2001, 64 (05) :287-294
[3]   THE COMBINED ORAL-CONTRACEPTIVE - RISKS AND ADVERSE-EFFECTS IN PERSPECTIVE [J].
BAGSHAW, S .
DRUG SAFETY, 1995, 12 (02) :91-96
[4]   Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol [J].
Bjarnadóttir, RI ;
Tuppurainen, M ;
Killick, SR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (03) :389-395
[5]   Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring [J].
Dieben, TOM ;
Roumen, FJME ;
Apter, D .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :585-593
[6]   Oral contraceptive estrogen dose considerations [J].
Kaunitz, AM .
CONTRACEPTION, 1998, 58 (03) :15S-21S
[7]   PHARMACOKINETICS OF LEVONORGESTREL AND ETHINYLESTRADIOL IN 9 WOMEN WHO RECEIVED A LOW-DOSE ORAL-CONTRACEPTIVE OVER A TREATMENT PERIOD OF 3 MONTHS AND, AFTER A WASH-OUT PHASE, A SINGLE ORAL-ADMINISTRATION OF THE SAME CONTRACEPTIVE FORMULATION [J].
KUHNZ, W ;
ALYACOUB, G ;
FUHRMEISTER, A .
CONTRACEPTION, 1992, 46 (05) :455-469
[8]  
Muirhead GJ, 2000, BRIT J CLIN PHARMACO, V49, p49S
[9]   Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel:: a randomized trial [J].
Oddsson, K ;
Leifels-Fischer, B ;
Wiel-Masson, D ;
de Melo, NR ;
Benedetto, C ;
Verhoeven, CHJ ;
Dieben, TOM .
HUMAN REPRODUCTION, 2005, 20 (02) :557-562
[10]   Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol [J].
Roumen, FJME ;
Apter, D ;
Mulders, TMT ;
Deiben, TOM .
HUMAN REPRODUCTION, 2001, 16 (03) :469-475
12